Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.34
0.010.43%
At close: Sep 11, 5:00 PM EST
$2.34
N/A
After Hours: 4:01 PM EST
Inhibikase Therapeutics Inc (IKT) Stock Price, Quote, News & History
IKTNASDAQ
Inhibikase Therapeutics (IKT) Stock Price, Quote, News & History | Benzinga
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Inhibikase Therapeutics (IKT) stock?
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Who are Inhibikase Therapeutics (IKT) competitors?
Other companies in Inhibikase Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
What is the forecast, or price target, for Inhibikase Therapeutics (IKT) stock?
Inhibikase Therapeutics has a consensus price target of $5.43.
What is the current price for Inhibikase Therapeutics (IKT)?
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.34 last updated September 11, 2026 at 4:01 PM EDT.
Does Inhibikase Therapeutics (IKT) pay a dividend?
There are no upcoming dividends for Inhibikase Therapeutics.
When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?
Inhibikase Therapeutics does not have any upcoming earnings scheduled.
Is Inhibikase Therapeutics (IKT) going to split?
There is no upcoming split for Inhibikase Therapeutics.
What sector and industry does Inhibikase Therapeutics (IKT) operate in?
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
